People · Operator
Named in public records as an officer, director or promoter · active 2010–2024 · Biotechnology, Other Technology, Media & Content, Business Services, Other Health Care, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lumicell, Inc. | — | Biotechnology | Series D+ | $331.1M | $1.7B | 2024 |
| Gelesis Inc | — | Biotechnology | Series B | $37.7M | $1.3B | 2015 |
| Core Informatics, LLC | — | Other Technology | Series B | $22.0M | $533.0M | 2014 |
| Centri Technology, Inc. | — | Other Technology | Series A | $15.9M | $175.9M | 2014 |
| Paperg, Inc | — | Other Technology | Series A | $13.3M | $189.8M | 2012 |
| Domino Media Group, Inc. | — | Media & Content | Series A | $10.9M | $6.7M | 2012 |
| Ubiquity Global Services, Inc. | — | Business Services | Series A | $4.0M | $83.1M | 2013 |
| Onebiopharma Inc. | — | Other Health Care | Seed | $3.0M | $74.4M | 2019 |
| Rivalries Unlimited LLC | — | Other | Seed | $2.6M | $48.3M | 2014 |
| Green Life Guides, LLC | — | Business Services | Pre-Seed | $881K | $6.3M | 2010 |
Elon Boms at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Elon Boms on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Roger Lee | 1 | 19 |
| Daniel Rosen | 1 | 13 |
| Rishi Gupta | 1 | 12 |
| David Furneaux | 1 | 8 |
| Dan Rosen | 1 | 8 |
| Andrey Zarur | 1 | 6 |
| Stefan Pepe | 1 | 5 |
| Amit Munshi | 1 | 5 |
| Robert Forrester | 1 | 4 |
| Eric Elenko | 1 | 4 |
| Jimmy Lu | 1 | 4 |
| Andrew Appelbaum | 1 | 3 |
| Raymond Iglesias III | 1 | 3 |
| Vaughan Emery | 1 | 2 |
| Wayne Wisehart | 1 | 2 |
| M. Wayne Wisehart | 1 | 2 |
| Rob Strickland | 1 | 2 |
| Aaron Wallace | 1 | 2 |
| Tyler Bosmeny | 1 | 2 |
| Christopher Oates | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.